Original ArticleTranslational OncologyPD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Keywords
Cited by (0)
Drs. McElhinny and Stanforth equally contributed to this work.
Disclosure: Dr. Hirsch has received compensation from Genentech/Roche, Pfizer, Bristol-Myers Squibb, Lilly, Merck & Co., Inc., AstraZeneca, Boehringer-Ingelheim, and Ventana/Roche for participating in advisory boards and has received research funding (through the University of Colorado) from Genetech/Roche, Bristol-Myers Squibb, Lilly, Bayer, Amgen, and Ventana/Roche. Mr. Stanforth is a full-time employee of Dako and owns stock in Dako. Dr. Ranger-Moore is a full-time employee of and owns stock in Roche. Ms. Jansson is a full-time employee of and owns stock in Dako. Dr. Kulangara is a full-time employee of and owns stock in Dako. Mr. Richardson and his spouse are full-time employees of Roche. Ms. Towne is a full-time employee of Ventana Medical Systems, Roche Tissue Diagnostics, and owns stock in Roche Diagnostics. Dr. Hanks is a full-time employee of and owns stock in Dako. Dr. Vennapusa is a full-time employee of Ventana Medical Systems, Roche Tissue Diagnostics. Dr. Mistry is a full-time employee of Ventana Medical Systems, Inc., and owns stock in F. Hoffmann-La Roche Ltd. Dr. Kalamegham is a full-time employee of Genentech Inc. Dr. Averbuch is a full-time employee of Bristol-Myers Squibb. Dr. Novotny is a full-time employee of Bristol-Myers Squibb. Dr. Rubin is a full-time employee of Merck & Co., Inc. Dr. Emancipator is a full-time employee of Merck & Co., Inc. and owns stock in Merck & Co., Inc., Bayer AG, and Johnson and Johnson. Dr. McCaffery's spouse was an employee and stockholder of Genentech/Roche during the writing of this study. Dr. Williams is an employee of Genentech. Dr. Walker is a full-time employee of and owns stock in AstraZeneca. Dr. Longshore has performed contract research for Agilent Technologies and Ventana; has received compensation from Ventana, AstraZeneca, Bristol-Myers Squibb, and Genentech for participating in advisory boards; and has received consultancy fees and/or honoraria from Ventana, AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck & Co., Inc. Dr. Tsao has received compensation from AstraZeneca, Merck & Co., Inc., Ventana/Roche, and Bristol-Meyers Squibb for participating in advisory boards and has received research funding (through the University Health Network) from Merck & Co., Inc., Canada. Mr. Kerr has received consultancy fees and/or honoraria from Roche/Genentech, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Inc., and Ventana. The remaining author declares no conflict of interest.